Free Trial

Aptose Biosciences (APS) Competitors

Aptose Biosciences logo
C$2.37 -0.01 (-0.42%)
As of 06/12/2025 04:10 PM Eastern

APS vs. PLI, ABCN, EMC, FRX, BCT, IPA, TH, SCYB, COM, and NVH

Should you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include ProMetic Life Sciences (PLI), VIVO Cannabis (ABCN), Emblem (EMC), Fennec Pharmaceuticals (FRX), BriaCell Therapeutics (BCT), ImmunoPrecise Antibodies (IPA), Theratechnologies (TH), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), and Novoheart (NVH). These companies are all part of the "biotechnology" industry.

Aptose Biosciences vs. Its Competitors

Aptose Biosciences (TSE:APS) and ProMetic Life Sciences (TSE:PLI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, community ranking, analyst recommendations, profitability, earnings and media sentiment.

Aptose Biosciences has higher earnings, but lower revenue than ProMetic Life Sciences. Aptose Biosciences is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/A-C$154.69M-C$5.02-0.47
ProMetic Life SciencesC$39.91M0.00-C$1.47B-C$63.06N/A

In the previous week, Aptose Biosciences' average media sentiment score of 0.00 equaled ProMetic Life Sciences'average media sentiment score.

Company Overall Sentiment
Aptose Biosciences Neutral
ProMetic Life Sciences Neutral

Aptose Biosciences' return on equity of 1,017.48% beat ProMetic Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Aptose BiosciencesN/A 1,017.48% -136.29%
ProMetic Life Sciences N/A N/A N/A

15.1% of Aptose Biosciences shares are held by institutional investors. 17.1% of Aptose Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Given ProMetic Life Sciences' higher possible upside, analysts plainly believe ProMetic Life Sciences is more favorable than Aptose Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aptose Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
4.00
ProMetic Life Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

ProMetic Life Sciences received 229 more outperform votes than Aptose Biosciences when rated by MarketBeat users. However, 72.20% of users gave Aptose Biosciences an outperform vote while only 67.69% of users gave ProMetic Life Sciences an outperform vote.

CompanyUnderperformOutperform
Aptose BiosciencesOutperform Votes
213
72.20%
Underperform Votes
82
27.80%
ProMetic Life SciencesOutperform Votes
442
67.69%
Underperform Votes
211
32.31%

Summary

Aptose Biosciences beats ProMetic Life Sciences on 8 of the 13 factors compared between the two stocks.

Get Aptose Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for APS and its competitors with MarketBeat's FREE daily newsletter.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APS vs. The Competition

MetricAptose BiosciencesBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$102.05MC$126.95MC$5.61BC$6.09B
Dividend Yield0.39%3.74%5.28%6.72%
P/E Ratio-0.473.2827.1435.87
Price / SalesN/A4,269.77416.101,010.47
Price / Cash1.6013.1938.2583.29
Price / Book-2.5936.927.074.24
Net Income-C$154.69M-C$91.56MC$3.23BC$301.20M
7 Day Performance-3.27%1.81%0.71%1.37%
1 Month Performance-6.69%7.63%9.65%5.56%
1 Year Performance-94.19%176.32%32.07%24.46%

Aptose Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APS
Aptose Biosciences
N/AC$2.37
-0.4%
N/A-93.5%C$102.05MN/A-0.4731Gap Up
High Trading Volume
PLI
ProMetic Life Sciences
N/AN/AN/AN/AC$317.06MC$39.91M-0.22487
ABCN
VIVO Cannabis
N/AC$1.32
+5.6%
N/A+0.0%C$256.62MN/A0.00N/AGap Up
EMC
Emblem
N/A$1.88
+1.6%
N/A+0.0%$245.45M$5.71M-9.89N/A
FRX
Fennec Pharmaceuticals
N/AC$11.16
-0.8%
N/A+20.6%C$215.22MC$34.86M-189.0510
BCT
BriaCell Therapeutics
N/AC$10.60
-3.8%
C$15.00
+41.5%
+0.0%C$168.68MN/A-28.195
IPA
ImmunoPrecise Antibodies
N/AC$6.50
+0.8%
N/A+0.0%C$162.08MC$19.47M-7.3080Gap Down
TH
Theratechnologies
N/AC$3.65
+4.0%
N/A+106.6%C$116.46MC$52.22M-41.32103
SCYB
Scythian Biosciences
N/AC$3.49
-5.9%
N/A+0.0%C$102.38MN/A0.00N/AHigh Trading Volume
COM
138267 (COM.TO)
N/AN/AN/AN/AC$102.19MN/A0.00N/A
NVH
Novoheart
N/AC$0.53
+1.9%
N/A+0.0%C$99.98MC$423.50K-13.95N/A

Related Companies and Tools


This page (TSE:APS) was last updated on 6/13/2025 by MarketBeat.com Staff
From Our Partners